Skip to main content

Table 1 Proportion of Pfk13, Pfmdr1 and Pfcrt polymorphisms in day 0, recurrent and recrudescent infections

From: Assessment of molecular markers of anti-malarial drug resistance among children participating in a therapeutic efficacy study in western Kenya

Polymorphism Pre-treatment (day 0) samples Recurrent infection samples Recrudescent samples
Pfk13a
 Samples successfully sequenced 317/323 (98.1%) 88/110 (80.0%) 23/24 (95.8%)
 Wild type (no or mixed mutations detected) 315/317 (99.4%) 87/88 (98.9%) 22/23 (95.7%)
 522C 2/317 (0.6%) 0 0
 578S 6/317 (1.9%) 2/88 (2.3%) 1/23 (4.3%)
Pfmdr1a
 Samples successfully sequenced 320/323 (99.1%) 95/110 (86.4%) 24/24 (100.0%)
 N86 319/320 (99.7%) 94/95 (98.9%) 23/24 (95.8%)
 86 N/Y 1/320 (0.3%) 0 0
 86Y 0 1/95 (1.1%) 1/24 (4.2%)
 Y184 129/320 (40.3%) 36/95 (37.9%) 8/24 (33.3%)
 184Y/F 79/320 (24.7%) 16/95 (16.8%) 5/24 (20.8%)
 184F 112/320 (35.0%) 43/95 (45.3%) 11/24 (45.8%)
 D1246 290/320 (90.6%) 90/95 (94.7%) 22/24 (91.7%)
 1246D/Y 19/320 (5.9%) 3/95 (3.2%) 2/24 (8.3%)
 1246Y 11/320 (3.4%) 2/95 (2.1%) 0
 NYD 203/320 (63.4%) 50/95 (52.6%) 13/24 (54.2%)
 YFD 1/320 (0.3%) 1/95 (1.1%) 1/24 (4.2%)
 NFD 185/320 (57.8%) 58/95 (61.1%) 15/24 (62.5%)
 NFY 18/320 (5.6%) 2/95 (2.1%) 1/24 (4.2%)
 NYY 21/320 (6.6%) 5/95 (5.3%) 2/24 (8.3%)
 YYD 1/320 (0.3%) 0 0
 YFY 0 0 0
 YYY 0 0 0
Pfcrta
 Samples successfully sequenced 318/323 (98.5%) 95/110 (86.4%) 24/24 (100.0%)
 C72 318/318 (100.0%) 95/95 (100.0%) 24/24 (100.0%)
 72S 0 0 0
 M74 314/318 (98.7%) 93/95 (97.9%) 23/24 (95.8%)
 74 M/I 2/318 (0.6%) 0 0
 74I 2/318 (0.6%) 2/95 (2.1%) 1/24 (4.2%)
 N75 312/318 (98.1%) 93/95 (97.9%) 23/24 (95.8%)
 75 N/D 4/318 (1.3%) 0 0
 75E 2/318 (0.6%) 2/95 (2.1%) 1/24 (4.2%)
 K76 312/318 (98.1%) 93/95 (97.9%) 23/24 (95.8%)
 76 K/T 4/318 (1.3%) 0 0
 76T 2/318 (0.6%) 2/95 (2.1%) 1/24 (4.2%)
 CVMNK 316/318 (99.4%) 93/95 (97.9%) 23/24 (95.8%)
 CVIDTb 2/318 (0.6%) 0 0
 CVMDTc 2/318 (0.6%) 0 0
 CVIET 2/318 (0.6%) 2/95 (2.1%) 1/24 (4.2%)
  1. Bold letter denotes an encoded amino acid change; aTotals may not sum due to mixed infections (samples with both wild and mutant codons) which were counted as both wild and mutant haplotypes). bTwo samples yielded the following findings for Pfcrt: C at site 72, M and I at site 74, N and D at site 75, K and T at site 76. These were considered mixed infections with CVMNK and CVIDT. cTwo samples yielded the following findings for Pfcrt: C at site 72, M at site 74, N and D at site 75, K and T at site 76. These were considered mixed infections with CVMNK and CVMDT